Posted by Michael Wonder on 21 Nov 2022
TLV subsidises anti-viral treatment of COVID-19 to risk groups
21 November 2022 - Paxlovid, which treats patients who are at risk of becoming seriously ill from COVID-19, will be included in the high-cost cover from November 19, the Dental Care and Pharmaceutical Benefits Agency has decided.
Paxlovid is an anti-viral medicine used to treat adults who do not need to be treated with oxygen but who are at increased risk of developing severe covid-19, for example people with advanced age or a weakened immune system.
